99% of U.S. Population Would Not Benefit From Mass Vaccination With Pfizer’s RNA Covid-19 Vaccine
News headlines claim 95% effectiveness for Pfizer RNA COVID-19 vaccine. In hard numbers, there is only a marginal (less than 1%) statistical advantage to vaccination compared to an inactive placebo vaccine. This deception will lead to massive overvaccination of the U.S. population.
Knowledge of Health, Dec. 9, 2020 – Analysis of data released by the FDA reveals mandated vaccination of the entire U.S. population with PFIZER’S COVID-19 RNA vaccine would prevent less than 1% of COVID-19 cases.
On December 10, 2020, the Food & Drug Administration, acting as a front-man for Pfizer drug company, released a seemingly positive report on the safety and effectiveness of a 2-dose RNA COVID-19 vaccine, claiming 95% effectiveness.
The design for this ongoing vaccine study is intended to determine how well an RNA-altering COVID-19 vaccine reduces incidence of COVID-19 infection as determined by a PCR (polymerase chain reaction) nasal swab test and by symptomology over a short-term (sometime 7 days after the 2nd inoculation). The PFIZER Report is available for viewing and analysis.
The 2-inoculation regimen is used to reduce dose-related side effects.
Both vaccinated and placebo groups experienced less than 1-percent infection rates in hard numbers, but on a relative basis vaccinated subjects experienced 95% less risk for infection.
The chance of benefiting from vaccination is less than 1-percent because very few are infected in the first place. This scheme hides the fact massive overvaccination needs to occur to produce a health benefit for very few.
Over all there were 9 cases of COVID-19 among 19,965 vaccinated subjects vs. 169 among 20,172 subjects in the placebo group. (9 divided by 169 = .05 or ~95% relative reduction in new cases of COVID-19). This is how investigators came up with the quoted 95% effectiveness for this vaccine.
It should not be misconstrued that 95% effectiveness means 95 out of 100 benefited from vaccination by reduction of risk for infection.
Over 38,000 subjects had to be inoculated to determine the number of lab-tested cases of COVID-19 were reduced from 169 to 9; (9 in 19,965 vaccinated subjects = 0.00045% or 4.5 cases in 10,000); compared to 162 COVID-19 infections among 20,172 that received an inactive placebo (0.00803% or 8 cases in 1000).
Extrapolated to entire US population (325,000,000)
If the data gleaned from the FDA/PFIZER vaccine report were applied and the entire U.S. population was vaccinated, the following chart reveals the number of infected cases would dramatically drop to 146,250 compared to 2,609,750 cases if an inactive placebo were administered, but 325,000,000 Americans would have to be inoculated to achieve these numbers, with no assurance immunity would last, with no assurance deaths would decline, and with uncertainty whether side effects will exceed benefits.
The RNA vaccine activated dormant viruses that resulted in cases of temporary facial nerve paralysis (Bell’s palsy) and could activate incapacitating Guillain barre syndrome, shingles and hepatitis.
A number of vaccines that have undergone more rigorous study than the current COVID-19 vaccines now being licensed
Article from LewRockwell